Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by TMAZZ21on Feb 14, 2023 5:46am

543 Views

Post# 35284536

PANCREATIC CANCER - 70% response rate & complete elimination

I assume you guys all heard this

https://open.spotify.com/episode/6r188KpoAGcft1KkZV69TV?si=ObmICTAtSW-BXDL9qkNvKg

If you go to the 18:26 minute and listen Mat goes on to say

That's what we are seeing here in pancreatic cancer, to be able to come in and see a 70% reponse rate and "that includes complete elmination of their disease"

Just keep replaying this part and let it sink in, when currently approx. 95% of people with pancreatic cancer die from it!

I'm sure everyone of these huge pharmaceutical companies will want to buyout Oncolytics!

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions